Lung cancer trials in China

In China 1143 Also abroad 2744

1,143 trials · From ClinicalTrials.gov, checked 12 November 2026. Ask the study team whether a trial fits you.

Phase 1/2Taking people
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Where
Baoding, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Taizhou, Tianjin, Wuhan, Xi’an, Xinxiang, Zhengzhou
Age
18 years and over
People
862 worldwide
Run by
DualityBio Inc.
See details and how to joinNCT05914116
No phaseTaking people
A Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in China
Where
Beijing
Age
18 years and over
People
3,000
Run by
AstraZeneca
See details and how to joinNCT07316062
No phaseTaking people
Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally Advanced or Metastatic NSCLC: A Multicenter, Prospective, Real-World Cohort Study
Where
Guangzhou
Age
18 years and over
People
265
Run by
Guangdong Association of Clinical Trials
See details and how to joinNCT07696832
Phase 2Not yet taking people in China
MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLC
Where
Beijing
Age
18 years and over
People
100
Run by
Peking University People's Hospital
See details and how to joinNCT07885709
Phase 1Taking people
Propranolol Hydrochloride Combined With Adebrelimab and Platinum-Based Chemotherapy in Small Cell Lung Cancer
Where
Changsha
Age
18 years to 75 years
People
18
Run by
Second Xiangya Hospital of Central South University
See details and how to joinNCT07886047
Phase 1Taking people
Propranolol Hydrochloride Combined With Toripalimab and Platinum-based Chemotherapy in Resectable Non-Small Cell Lung Cancer
Where
Changsha
Age
18 years to 75 years
People
9
Run by
Second Xiangya Hospital of Central South University
See details and how to joinNCT07886229
Phase 3Taking people
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
Where
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jiangxi, Jinan, Kunming, Linyi, Nanchang, Nanjing, Shanghai, Shanxi, Shenzhen, Tianjin, Weifang, Wuhan, Xiamen, Xi’an, Xinxiang, Yangzhou, Zhengzhou
Age
18 years and over
People
695 worldwide
Run by
Gilead Sciences
See details and how to joinNCT06801834
No phaseNot yet taking people in China
Diagnostic Performance of an AI-Based Multi-Omics Model for Early Lung Cancer
Where
Beijing, Changsha
Age
18 years to 75 years
People
1,050
Run by
Beijing Chao Yang Hospital
See details and how to joinNCT07882628
Phase 1/2Taking people
Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer
Where
Shanghai
Age
18 years to 75 years
People
265
Run by
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
See details and how to joinNCT06283719
Phase 2Taking people
A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLC
Where
Jinan
Age
18 years to 75 years
People
120
Run by
Shanghai Hengrui Pharmaceutical Co., Ltd.
See details and how to joinNCT07798947
Phase 1Taking people
A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
Where
Beijing, Ch’ang-ch’un, Changsha, Chengdu, Guangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Shanghai, Shenyang, Wuhan, Xiamen, Xi’an, Zhengzhou
Age
18 years and over
People
339 worldwide
Run by
Zai Lab (Shanghai) Co., Ltd.
See details and how to joinNCT06179069
Phase 1/2Taking people
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Where
Beijing, Changsha, Chongqing, Harbin, Jinan, Nanchang, Shenyang, Zhengzhou
Age
18 years to 75 years
People
480 worldwide
Run by
Avenzo Therapeutics, Inc.
See details and how to joinNCT07038343
Phase 3Taking people
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
Where
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Heilongjiang, Jinan, Linyi, Nanchang, Naning, Nanjing, Shanghai, Shijiazhuang, Taizhou, Wuhan, Xiamen, Xi’an, Zhengzhou
Age
18 years and over
People
480 worldwide
Run by
Zai Lab (Shanghai) Co., Ltd.
See details and how to joinNCT07218146
Phase 4Taking people
Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.
Where
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Nanchang, Nanjing, Ningbo, Shanghai, Shenyang, Tianjin, Wuhan, Xi'an, Zhengzhou
Age
18 years and over
People
100
Run by
AstraZeneca
See details and how to joinNCT07279935
No phaseTaking people
Barriers and Facilitators of Persistence With Adjuvant Osimertinib
Where
Beijing
Age
18 years and over
People
100
Run by
AstraZeneca
See details and how to joinNCT07542210
Phase 2Not yet taking people in China
Firmonertinib Plus Chemotherapy for Unresectable EGFR PACC-Mutant Stage III Lung Cancer: A Phase II Study
Where
Changsha
Age
18 years and over
People
27
Run by
Hunan Province Tumor Hospital
See details and how to joinNCT07878871
Phase 1Taking people
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Where
Changsha, Chengdu, Guangzhou, Nanjing, Wenzhou
Age
18 years and over
People
453 worldwide
Run by
Pfizer
See details and how to joinNCT03460977 · EU 2023-509179-18-00
Phase 2Taking people
A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
Where
Changsha, Chengdu, Deyang, Dongguan, Fuzhou, Guangzhou, Hangzhou, Hefei, Linyi, Mianyang, Nanchang, Shantou, Shenyang, Wuhan, Zhengzhou, Zhuhai
Age
18 years and over
People
278 worldwide
Run by
AstraZeneca
See details and how to joinNCT07098338 · EU 2025-524843-11-00
No phaseTaking people
68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
Where
Beijing
Age
18 years and over
People
50
Run by
Peking University Third Hospital
See details and how to joinNCT07760012
No phaseTaking people
Effectiveness and Safety of MRG003 (Becotatug Vedotin) in Relapsed SCLC
Where
Shanghai
Age
18 years and over
People
52
Run by
Shanghai Pulmonary Hospital, Shanghai, China
See details and how to joinNCT07874581
Phase 2Not yet taking people in China
Intestinal Low-Dose Radiotherapy Combined With Immune Checkpoint Inhibitors in Solid Tumors With Liver Metastases
Where
Hangzhou
Age
18 years and over
People
120
Run by
Bing Xia
See details and how to joinNCT07875465
Phase 1Not yet taking people in China
Phase 1 Study of NW-301V TCR-T Cells in Advanced Solid Tumors With KRAS G12V Mutation
Where
Beijing, Hangzhou
Age
18 years to 75 years
People
66
Run by
Neowise Biotechnology
See details and how to joinNCT07875920
Phase 3Taking people
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
Where
Baoding, Beijing, Bengbu, Changchun, Fuzhou, Guangzhou, Ha’erbin, Hangzhou, Hebei, Hefei, Jiamusi, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shantou, Suzhou, Taiyuan, Wanzhou, Wenzhou, Wuhan, Xiangyang, Xinxiang, Yangzhou, Zhejiang, Zhengzhou
Age
18 years and over
People
621 worldwide
Run by
BioNTech SE
See details and how to joinNCT06712355 · EU 2024-515765-34-00
Phase 1Taking people
HS-IT101 Injection for Advanced NSCLC(FASTIL-Lung01)
Where
Guangzhou
Age
18 years to 75 years
People
12
Run by
Hangzhou Huasai Biomedicine Co., Ltd.
See details and how to joinNCT07105176
Phase 2Taking people
A Study of YL202 in Patients With Advanced Solid Tumors
Where
Changsha
Age
18 years and over
People
100
Run by
MediLink Therapeutics (Suzhou) Co., Ltd.
See details and how to joinNCT07202364